Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

Highlights • Conjugate pneumococcal polysaccharide vaccine allows for recall immune response. • This recall response occurs after follow-on use of conjugate or polysaccharide. • Polysaccharide vaccine results in diminished responses to subsequent conjugate. • When the use of both vaccines is conside...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-04, Vol.32 (20), p.2364-2374
Hauptverfasser:	Greenberg, Richard N, Gurtman, Alejandra, Frenck, Robert W, Strout, Cynthia, Jansen, Kathrin U, Trammel, James, Scott, Daniel A, Emini, Emilio A, Gruber, William C, Schmoele-Thoma, Beate
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Alcoholism Allergy and Immunology Applied microbiology Bacteriology Biological and medical sciences Confidence intervals Disease Double-Blind Method Female Fever Fundamental and applied biological sciences. Psychology Humans Immune response Immunization Schedule Male Microbiology Middle Aged Miscellaneous Mortality Muscle pain Phagocytosis Pneumococcal conjugate vaccine Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumonia Recall responses Streptococcus pneumoniae Streptococcus pneumoniae - classification Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Conjugate - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Conjugate pneumococcal polysaccharide vaccine allows for recall immune response. • This recall response occurs after follow-on use of conjugate or polysaccharide. • Polysaccharide vaccine results in diminished responses to subsequent conjugate. • When the use of both vaccines is considered, conjugate should be given first.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.02.002